Kurum Yazarı "Sevindik, Ömür Gökmen" Bildiri Koleksiyonu İçin Listeleme
-
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
A case series of CML patients who were presented with isolated thrombocytosis
Karakuş, Volkan; Aslan, Vedat; Parça, Güleycan; Sevindik, Ömür Gökmen; Keklik Karadağ, Fatma; Kurtoğlu, Erdal; Saydam, Güray (American Society of Hematology, 2022)Per WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology
Karakuş, Volkan; Sevindik, Ömür Gökmen; Karataş, Aylin; Yenihayat, Emel Merve; Polat, Merve Gökçen; Çelik, Serhat; Pınar, İbrahim Ethem; Alacacıoğlu, İnci (American Society of Hematology, 2022)Abstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database ... -
Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.
Özcan, Muhit; Lee, Seung Tae; Mensah, Felix; Modi, Dipenkumar; Fossa, Alexander; Kim, Won Seog; Paszkiewicz-Kozik, Ewa; Sevindik, Ömür Gökmen; Lavie, David (Lippincott Williams & Wilkins, 2023)...